Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-κB binding activity

Thiazolidinediones such as pioglitazone have been shown to exert anti-inflammatory effects independent of their insulin sensitizing effects by reducing activation of the proinflammatory transcription factor NF-κB in animal models of experimental diabetes. Furthermore, short-term pioglitazone treatment ameliorates endothelial dysfunction in conduit arteries of patients with type 2 diabetes. Since inflammation is supposed to impair flow-mediated vasodilatation, we studied the effects of an 8-week pioglitazone intervention on endothelial function and mononuclear NF-κB activation in patients with type 2 diabetes. Twenty patients were included in a randomized, double-blind, placebo-controlled study receiving 30 mg pioglitazone or placebo, respectively. Flow-mediated endothelium dependent vasodilatation (FMD) of the brachial artery, NF-κB binding activity in peripheral blood mononuclear cells [pBMC, determined by electrophoretic mobility shift assay (EMSA)] and interleukin-6 (IL-6)-transcription rates (determined by real-time PCR) were measured at study entry and after eight weeks of intervention. Pioglitazone treatment resulted in a significant improvement of FMD (4.3%±3.3; p=0.003), while no effect was seen under placebo medication (2.0%±2.7; p=0.71). The correction of FMD was neither paralleled by a pioglitazone-dependent reduction in mononuclear NF-κB binding activity (ΔNF-κB activity: pioglitazone: 9.2%±6.7, p=0.24; placebo: 5.7%±19.6; p=0.82) nor in NF-κB dependent gene transcription as determined for IL-6 (AIL-6 pioglitazone: +1.8%±12.0, p=0.93; placebo: -0.2%±9.7; p=0.92). These data demonstrate for the first time that pioglitazone treatment improves endothelial dysfunction in patients with type 2 diabetes without affecting NF-κB binding activity and NF-κB dependent proinflammatory gene expression in pBMC.